Skip to main content
SpringerLink
Log in

Sertraline treatment for depression associated with acute coronary syndromes: a cost analysis from the viewpoint of the Italian Healthcare System

  • Original Article
  • Published:
Aging Clinical and Experimental Research Aims and scope Submit manuscript

Abstract

Background and aims: Depressive disorders (DD) are independent risk factors for rehospitalization after acute coronary syndromes (ACS) and, hence, for increased healthcare costs. A placebo-controlled safety trial of 24 weeks of treatment with sertraline after ACS (Sertraline Anti-Depressant Heart Attack Randomized Trial, SADHART) suggested that active treatment was associated with reduced rehospitalization due to coronary and non-coronary events. With the SADHART database, a cost analysis was carried out to determine the economic consequences of treating DD after ACS in the perspective of the Italian Healthcare System. Methods: Clinical information on medical events and rehospitalizations recorded over the study period was drawn from the original SADHART database, which did not contain information necessary for estimating indirect costs. Analysis was therefore limited to direct medical costs due to rehospitalizations, emergency room visits and hospital procedures, and the average Italian Diagnosis-Related Group (DRG) tariffs were applied. Results: With the exclusion of the cost of sertraline treatment, the average direct cost per patient over the study period was 3,418±8,290 € in the active treatment group and 4,409±9,439 € in the placebo group (p=0.3). After including the cost of 24 weeks of sertraline treatment, the average cost in sertraline-treated patients was only modestly increased, to 3,524±8,290 €. Conclusions: Treatment of major DD in patients with recent ACS can improve patient care without additional costs, and possibly with some savings, to the healthcare system.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jiang W, Alexander J, Christopher E, et al. Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch Intern Med 2001; 161: 1849–56.

    Article  PubMed  CAS  Google Scholar 

  2. Carney RM, Rich MW, Freedland KE, et al. Major depressive disorder predicts cardiac events in patients with coronary artery disease. Psychosom Med 1988; 50: 627–33.

    PubMed  CAS  Google Scholar 

  3. Schleifer SJ, Macari H, Coyle DA, et al. The nature and course of depression following myocardial infarction. Arch Intern Med 1989; 149: 1785–9.

    Article  PubMed  CAS  Google Scholar 

  4. Frasure Smith N, Lesperance F, Talajic M. Depression following myocardial infarction. Impact on 6-month survival. JAMA 1993; 270: 1819–25.

    Article  PubMed  CAS  Google Scholar 

  5. Gonzalez MB, Snyderman TB, Colket JT, et al. Depression in patients with coronary artery disease. Depression 1996; 4: 57–62.

    Article  PubMed  CAS  Google Scholar 

  6. Mecocci P, Cherubini A, Mariani E, et al. Depression in the elderly: new concepts and therapeutic approaches. Aging Clin Exp Res 2004; 16: 176–89.

    PubMed  Google Scholar 

  7. Frasure Smith N, Lesperance F, Talajic M. Depression and 18-month prognosis after myocardial infarction. Circulation 1995; 91: 999–1005.

    Article  PubMed  CAS  Google Scholar 

  8. Rumsfeld JS, Jones PG, Whooley MA, et al. Depression predicts mortality and hospitalization in patients with myocardial infarction complicated by heart failure. Am Heart J 2005; 150: 961–7.

    Article  PubMed  Google Scholar 

  9. Parashar S, Rumsfeld JS, Spertus JA, et al. Time course of depression and outcome of myocardial infarction. Arch Intern Med 2006; 166: 2035–43.

    Article  PubMed  Google Scholar 

  10. Lesperance F, Frasure Smith N, Juneau M, Theroux P. Depression and 1-year prognosis in unstable angina. Arch Intern Med 2000; 160: 1354–60.

    Article  PubMed  CAS  Google Scholar 

  11. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 2000; 160: 2101–7.

    Article  PubMed  CAS  Google Scholar 

  12. Carney RM, Rich MW, teVelde A, et al. The relationship between heart rate, heart rate variability and depression in patients with coronary artery disease. J Psychosom Res 1988; 32: 159–64.

    Article  PubMed  CAS  Google Scholar 

  13. Carney RM, Saunders RD, Freedland KE, Stein P, Rich MW, Jaffe AS. Association of depression with reduced heart rate variability in coronary artery disease. Am J Cardiol 1995; 76: 562–4.

    Article  PubMed  CAS  Google Scholar 

  14. Carney RM, Blumenthal JA, Stein PK, et al. Depression, heart rate variability, and acute myocardial infarction. Circulation 2001; 104: 2024–8.

    Article  PubMed  CAS  Google Scholar 

  15. Pitzalis MV, Iacoviello M, Todarello O, Johnson PC, Finkel MS. Depression but not anxiety influences the autonomic control of heart rate after myocardial infarction. Am Heart J 2001; 141: 765–71.

    Article  PubMed  CAS  Google Scholar 

  16. Laghrissi Thode F, Wagner WR, Pollock BG, Johnson PC, Finkel MS. Elevated platelet factor 4 and beta-thromboglobulin plasma levels in depressed patients with ischemic heart disease. Biol Psychiatry 1997; 42: 290–5.

    Article  PubMed  CAS  Google Scholar 

  17. Pollock BG, Laghrissi Thode F, Wagner WR. Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. J Clin Psychopharmacol 2000; 20: 137–40.

    Article  PubMed  CAS  Google Scholar 

  18. McFarlane A, Kamath MV, Fallen EL, Malcolm V, Cherian F, Norman G. Effect of sertraline on the recovery rate of cardiac autonomic function in depressed patients after acute myocardial infarction. Am Heart J 2001; 142: 617–23.

    Article  PubMed  CAS  Google Scholar 

  19. Monster TB, Johnsen SP, Olsen ML, McLaughlin JK, Sørensen HT. Antidepressants and risk of first-time hospitalization for myocardial infarction: a population-based case-control study. Am JMed 2004; 117: 732–7.

    CAS  Google Scholar 

  20. Taylor CB, Youngblood ME, Catellier D, et al. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry 2005; 62: 792–8.

    Article  PubMed  CAS  Google Scholar 

  21. Glassman AH, Connor CM, Califf RM, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002; 288: 701–9.

    Article  PubMed  CAS  Google Scholar 

  22. Frasure-Smith N, Lesperance F, Gravel G, et al. Depression and health-care costs during the first year following myocardial infarction. J Psychosom Res 2000; 48: 471–8.

    Article  PubMed  CAS  Google Scholar 

  23. Croghan TW, Obenchain RL, Crown WE. What does treatment of depression really cost? Health Aff (Millwood) 1998; 17: 198–208.

    Article  CAS  Google Scholar 

  24. O’Connor CM, Glassman AH, Harrison DJ. Pharmacoeconomic analysis of sertraline treatment of depression in patients with unstable angina or a recent myocardial infarction. J Clin Psychiatry 2005; 66: 346–52.

    Article  PubMed  Google Scholar 

  25. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56–62.

    Article  PubMed  CAS  Google Scholar 

  26. Guy W. ECDEU Assessment Manual for Psychopharmacology. Washington (DC, USA): U.S. Government Printing Office., 1976.

  27. Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 1977; 296: 716–21.

    Article  PubMed  CAS  Google Scholar 

  28. Drummond M, Stoddart G, Torrance G. Methods for economic evaluation of health care programmes. Oxford (UK): Oxford University Press, 1997.

    Google Scholar 

  29. Von Korff M, Ormel J, Katon W, Lin EH. Disability and depression among high utilizers of health care. A longitudinal analysis. Arch Gen Psychiatry 1992; 49: 91–100.

    Article  Google Scholar 

  30. Ormel J, Vonkorff M, Ustun TB, Pini S, Korten A, Oldehinkel T. Common mental disorders and disability across cultures. Results from the WHO Collaborative Study on Psychological Problems in General Health Care. JAMA 1994; 272: 1741–8.

    Article  PubMed  CAS  Google Scholar 

  31. Baldwin D. The cost of treating and not treating depression. Available at: http://www.depression-webworld.com/cost_depressionndx.htm. Accessed January, 2007.

  32. Dardennes R, Berdeaux G, Lafuma A, Fagnani F. Comparison of the cost-effectiveness of milnacipran (a SNRI) with TCAs and SS-RIs: a modeling approach. Eur Psychiatry 1999; 14: 152–62.

    Article  PubMed  CAS  Google Scholar 

  33. Doogan DP, Caillard V. Sertraline in the prevention of depression. Br J Psychiatry 1992; 160: 217–22.

    Article  PubMed  CAS  Google Scholar 

  34. Swenson JR, Connor CM, Barton D, et al. Influence of depression and effect of treatment with sertraline on quality of life after hospitalization for acute coronary syndrome. Am J Cardiol 2003; 92: 1271–6.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Scientific Direction, Italian National Research Centre on Aging (INRCA), via S. Margherita 5, 60124, Ancona, Italy

    Fabrizia Lattanzio MD, PhD

  2. Institute of Gerontology and Geriatrics, Department of Clinical and Experimental Medicine, University of Perugia, Italy

    Antonio Cherubini

  3. National and Regional HealthCare Affairs Department, Pfizer Italia, Roma

    Gianluca Furneri

  4. Unit of Gerontology and Geriatrics, Department of Critical Care Medicine and Surgery, University of Firenze, and Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy

    Mauro Di Bari & Niccolò Marchionni

Authors
  1. Fabrizia Lattanzio MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Antonio Cherubini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gianluca Furneri
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mauro Di Bari
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Niccolò Marchionni
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fabrizia Lattanzio MD, PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lattanzio, F., Cherubini, A., Furneri, G. et al. Sertraline treatment for depression associated with acute coronary syndromes: a cost analysis from the viewpoint of the Italian Healthcare System. Aging Clin Exp Res 20, 76–80 (2008). https://doi.org/10.1007/BF03324751

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03324751

Keywords

Search

Navigation